What Retatrutide Changed in Early Human Tests

What the first human tests showed

Retatrutide is being tested in Phase 3. It acts like GLP-1 and two other hormones tied to hunger, blood sugar, and fuel use. The FDA and other agencies hadn’t approved it by mid-2026. Phase 3 is the last large testing round before a company may seek approval.

Earlier results drew attention. In a 48-week weight study, the 12 mg group lost far more than the placebo group ^[20]. A 36-week Phase 2 test found lower blood sugar at 24 weeks and lower weight at 36 weeks in people with type 2 diabetes ^[21]. A second Phase 2 test found less liver fat at 24 weeks; 86% of people reached under 5% liver fat ^[19]. Phase 2 is an early human round. Another Phase 2 result may change later. It can’t settle long-term safety, and later findings may change the answer.

Some people call retatrutide “GLP-3,” a made-up label that wrongly suggests a third kind of one gut hormone. Retatrutide instead follows two gut hormones plus glucagon, which affects blood sugar and stored fuel. Ask which test best matches your age and health. You’ll still need the later results.

What its three hormone actions may change

Retatrutide is made from protein parts. A fat-like part helps the drug remain in your blood longer. That design fact can’t prove safe use or predict your result.

Tirzepatide follows two gut hormones, including GLP-1. Retatrutide follows those two and glucagon, a hormone that can release sugar and push your body to draw on stored fuel. Researchers hope the three actions bring more weight loss. In cells kept in a dish, retatrutide reacted with all three hormone message points ^[18]. That test confirmed the drug’s three actions. It didn’t test benefit or harm in a person. Cell work also can’t tell whether your heart risk would change. That’s why cell work can’t settle your choice.

How hunger, blood sugar, and pulse may change

The three hormones have different jobs.

• GLP-1, the first gut hormone, helps your pancreas release insulin when blood sugar rises. It also slows your stomach and eases hunger.
• The second gut hormone may add help with insulin and hunger. Tirzepatide follows this hormone as well.
• Glucagon may release sugar from your liver and help use stored fuel. The two gut hormones may soften that sugar rise.

Phase 2, the second human test round, also found a faster pulse. Glucagon can speed the heart, so doctors are watching this risk. That Phase 2 finding grew with higher study amounts. Average pulse reached its high point near 24 weeks ^[20][17]. Longer heart tests are still needed. Tell the study doctor about a racing or pounding heart. If you enter a study, ask when your pulse will be checked.

What four studies and a review found

Early weight test. In 2023, 338 adults joined a Phase 2 study for 48 weeks. The 12 mg group lost far more weight than the placebo group. Stomach and bowel trouble was mainly mild or moderate. Pulse rose more with higher study amounts and peaked near 24 weeks ^[20].

Early type 2 diabetes test. In 2023, 281 adults joined Phase 2 for 36 weeks. The 12 mg group had lower blood sugar at 24 weeks and lower weight at 36 weeks. Stomach and bowel trouble affected 35%. No one had dangerously low blood sugar or died ^[21].

Liver-fat test. In 2024, 98 adults with at least 10% liver fat took part for 48 weeks. The 12 mg group had much less liver fat by 24 weeks. In all, 86% reached under 5% liver fat. The improvement remained at 48 weeks ^[19].

Cells studied in 2024. In a dish, retatrutide reacted at the three places used by those hormones ^[18]. No person or animal was tested.

A review. Phase 1 came first. Phase 1/2 means the first two human test rounds. The 2025 paper covered both and reported a top weight loss of about 24% in the 12 mg group. It said in 2025 that Phase 3 work was still underway ^[17]. Ask whether the people studied shared your age and health. Then ask what the early test can’t say about your risk. You can take those two questions to your visit.

What people report and what still needs study

They're personal reports from people using products sold as retatrutide. They aren’t results from the Phase 2 studies, and no study has counted them under one set of rules: Some people say thoughts about food nearly stop. Others mention fast weight loss, warmth, a flushed face, or a quicker pulse. Nausea, rotten-egg burps, constipation, and early tiredness also come up. The products and amounts can’t be checked.

Human studies leave these risks and questions:

• No approval: Retatrutide has no FDA approval. Products sold outside a study can’t be checked for contents, cleanliness, or strength. The FDA sent more than 50 warning letters to sellers in 2025 under Federal law.
• Stomach and bowel trouble: Nausea affected up to 45% in the highest Phase 2 group. It was the main reason 18% of that group stopped.
• Faster pulse: Phase 2 found an average rise that peaked near 24 weeks ^[20]. A long heart study is still underway, so lasting heart effects aren’t known.
• Muscle loss: People in Phase 2 lost muscle and other tissue that wasn’t fat, as well as fat. Fast loss can be hard on older adults.
• Long-term questions: Phase 3 studies numbered 1/2/3 were still running in mid-2026. They haven’t answered the long-term questions.
• Weight after stopping: Weight often returns after people stop similar medicines. As a GLP-1 type medicine, retatrutide doesn’t yet have its own long record. Personal reports can’t tell you your risk. Your doctor can help list the unknowns that affect you. You won’t find long-term proof in those reports.

Questions about a drug with no approval

Retatrutide has more human work than BPC-157 and less than the three approved medicines. Phase 2 brought strong early findings. Phase 2 still leaves open questions. Those results still need larger tests. Phase 3 is the much bigger late round. Phase 3 comes next. Even a finished Phase 3 study doesn’t mean FDA approval.

Ask what doctors truly know about people your age with your health history. Ask which heart, muscle, and blood sugar changes need watching. A product outside a proper study may contain something different. There’s no approved price or usual visit plan yet.

I’d ask who checks on you and whom you call if your pulse or stomach changes. The comparison with approved medicines puts those limits beside the stronger proof.